Core Insights - Silo Pharma, Inc. has selected Allucent to assist in the final preparations for its investigational new drug application (IND) for the Phase 1 clinical trial of its intranasal prophylactic SPC-15 aimed at treating PTSD, with plans to submit the IND in 2026 [1][2] - The partnership with Allucent is viewed as a significant advancement in bringing the PTSD therapeutic to clinical trials, leveraging Allucent's expertise to ensure a robust IND submission [2] - Silo Pharma's therapeutic focus includes addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases, with a portfolio that includes SPC-15 for PTSD and other programs targeting fibromyalgia and Alzheimer's disease [3] Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, focusing on innovative programs for various medical conditions [3] - The company collaborates with leading universities and laboratories to conduct its research [3] Allucent Overview - Allucent is a global full-service clinical research organization with over 30 years of experience, providing comprehensive drug development solutions across various therapeutic areas [4] - The organization aims to assist biopharma and government clients in overcoming challenges in bringing new therapies to market [4]